Compare HG & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HG | ABCL |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | 2020 |
| Metric | HG | ABCL |
|---|---|---|
| Price | $38.32 | $9.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $39.86 | $18.69 |
| AVG Volume (30 Days) | 404.0K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | ★ 51.23 | 10.91 |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $2,905,524,000.00 | $75,128,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.38 | $13.74 |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | 24.70 | ★ 160.56 |
| 52 Week Low | $25.53 | $2.75 |
| 52 Week High | $39.50 | $14.98 |
| Indicator | HG | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 33.61 |
| Support Level | $33.53 | $3.45 |
| Resistance Level | N/A | $12.91 |
| Average True Range (ATR) | 0.99 | 0.84 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 71.43 | 1.84 |
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.